« Back
Home /
Anti-PCSK9 Antibody

Anti-PCSK9 Antibody

Item no.	BOS-A00085
Manufacturer	Boster
Amount	100 ul
Category	Neuroscience Metabolism Glucose Homeostasis Cholesterol & Lipid Metabolism Molecular Targets for Neuroscience Obesity Western Blot Immunofluorescence Immunocytochemistry Lipoprotein Receptors & Associated Proteins Immunochemistry
Format	Liquid
Applications	WB, IF, ICC
Specific against	Human (Homo sapiens), Mouse (Murine, Mus musculus), Rat (Rattus norvegicus)
Host	Rabbit
Alias	Proprotein convertase subtilisin/kexin type 9,3.4.21.-,Neural apoptosis-regulated convertase 1,NARC-1,Proprotein convertase 9,PC9,Subtilisin/kexin-like protease PC9,PCSK9,NARC1,PSEC0052
Available
Manufacturer - Category	Primary Antibodies
Storage Conditions	Store at -20°C for one year. For short term storage and frequent use, store at 4°C for up to one month. Avoid repeated freeze-thaw cycles.
Molecular Weight	74286 MW
Clonality	Polyclonal
Application Details	WB: 1:500-1:2000 ICC/IF: 1:50-1:200
Gene Name	PCSK9
Gene Full Name	Proprotein convertase subtilisin/kexin type 9
Immunogen	A synthetic peptide of human Proprotein Convertase 9(PCSK9)(NP_777596.2).
Contents	Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2
Purification	The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Concentration	1 mg/ml
Protein Name	Proprotein convertase subtilisin/kexin type 9
Protein Function	Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non- acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na (+) channel (ENaC)- mediated Na (+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
Subcellular Localization	Cytoplasm. Secreted. Endosome. Lysosome. Cell surface. Endoplasmic reticulum. Golgi apparatus. Autocatalytic cleavage is required to transport it from the endoplasmic reticulum to the Golgi apparatus and for the secretion of the mature protein. Localizes to the endoplasmic reticulum in the absence of LDLR and colocalizes to the cell surface and to the endosomes/lysosomes in the presence of LDLR. The sorting to the cell surface and endosomes is required in order to fully promote LDLR degradation.
Description	Boster Bio Anti-PCSK9 Antibody catalog # A00085. Tested in WB, ICC/IF applications. This antibody reacts with Human, Mouse, Rat.
Tissue Specificity	Expressed in neuro-epithelioma, colon carcinoma, hepatic and pancreatic cell lines, and in Schwann cells.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

BOS-A00085-datasheet.pdf

BOS-A00085-safety-datasheet.pdf